KDR and mycosis fungoides: Additional combinations under active study in TCL include pembrolizumab with brentuximab vedotin (NCT05313243); camrelizumab (PD-1 inhibitor) with pegasparaginase and apatinib (VEGFR2 inhibitor) in ENKTL (NCT04366128); nivolumab with chemotherapy for relapsed ALCL (NCT07013565); duvelisib and nivolumab in mycosis fungoides (MF) and Sezary Syndrome (SS) (NCT04652960); sintilimab (PD-L1 inhibitor) with gemcitabine and oxaliplatin (NCT04127227); and durvalumab with different combinations of pralatrexate, romidepsin, and oral azacitidine (NCT03161223).